DK1874313T3 - Behandling eller forebyggelse af ovarielt hyperstimulationssyndrom (OHSS) ved anvendelse af en dopaminagonist - Google Patents

Behandling eller forebyggelse af ovarielt hyperstimulationssyndrom (OHSS) ved anvendelse af en dopaminagonist

Info

Publication number
DK1874313T3
DK1874313T3 DK06744549.4T DK06744549T DK1874313T3 DK 1874313 T3 DK1874313 T3 DK 1874313T3 DK 06744549 T DK06744549 T DK 06744549T DK 1874313 T3 DK1874313 T3 DK 1874313T3
Authority
DK
Denmark
Prior art keywords
dopamine agonist
ovarian hyperstimulation
hyperstimulation syndrome
ohss
prevention
Prior art date
Application number
DK06744549.4T
Other languages
English (en)
Inventor
Antonio Pellicer-Martinez
Joan-Carlos Arce
Carlos Simon-Valles
Raul Gomez-Gallego
Original Assignee
Ferring Int Ct Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Int Ct Sa filed Critical Ferring Int Ct Sa
Application granted granted Critical
Publication of DK1874313T3 publication Critical patent/DK1874313T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06744549.4T 2005-04-29 2006-04-24 Behandling eller forebyggelse af ovarielt hyperstimulationssyndrom (OHSS) ved anvendelse af en dopaminagonist DK1874313T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67616505P 2005-04-29 2005-04-29
PCT/IB2006/000989 WO2006117608A1 (en) 2005-04-29 2006-04-24 Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist

Publications (1)

Publication Number Publication Date
DK1874313T3 true DK1874313T3 (da) 2010-11-15

Family

ID=36699199

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06744549.4T DK1874313T3 (da) 2005-04-29 2006-04-24 Behandling eller forebyggelse af ovarielt hyperstimulationssyndrom (OHSS) ved anvendelse af en dopaminagonist

Country Status (13)

Country Link
US (1) US8334298B2 (da)
EP (1) EP1874313B8 (da)
AT (1) ATE475420T1 (da)
CA (1) CA2605972C (da)
DE (1) DE602006015796D1 (da)
DK (1) DK1874313T3 (da)
ES (1) ES2349657T3 (da)
JO (1) JO2658B1 (da)
PL (1) PL1874313T3 (da)
PT (1) PT1874313E (da)
RU (1) RU2416410C2 (da)
TW (1) TWI315668B (da)
WO (1) WO2006117608A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7303772B2 (en) * 2005-11-10 2007-12-04 Olalde Rangel Jose Angel Synergistic phytoceutical compositions
SA08290041B1 (ar) * 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
KR101160225B1 (ko) 2007-02-01 2012-07-11 페링 인터내셔널 센터 에스 에이 자궁 내막증 치료용 약제
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
ITTO20070479A1 (it) * 2007-07-02 2009-01-03 Ceva Vetem S P A Composizione veterinaria iniettabile ad attivita' anti-prolattinica
EP3017809A1 (en) 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
RU2603319C1 (ru) * 2015-09-09 2016-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения больных с тяжелыми формами синдрома гиперстимуляции яичников
RU2637430C1 (ru) * 2016-06-29 2017-12-04 Федеральное государственное бюджетное учреждение "Эндокринологический научный центр" Министерства здравоохранения Российской Федерации Способ выбора тактики ведения пациентов с резистентными к консервативному лечению пролактин-секретирующими аденомами гипофиза на основе анализа индивидуальных особенностей фармакодинамики каберголина
US20210145788A1 (en) * 2019-11-15 2021-05-20 Thomas W MacAllister Methods of Treating Ascites
WO2023031218A1 (en) 2021-08-31 2023-03-09 Ferring B.V. Diagnosis and treatment of ectopic endometriosis
WO2024153752A1 (en) 2023-01-20 2024-07-25 Ferring B.V. Stereoselective synthesis of intermediates and synthesis of quinagolids
CN116806776B (zh) * 2023-08-03 2024-06-18 上海交通大学医学院附属第九人民医院 一种ohss小鼠模型及其构建方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88619I2 (fr) 1981-10-16 1995-07-10 Sandoz Ag QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JP2005530745A (ja) 2002-05-02 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ阻害剤
EP1558609A4 (en) 2002-10-30 2008-05-28 Merck & Co Inc KINASE INHIBITORS

Also Published As

Publication number Publication date
ATE475420T1 (de) 2010-08-15
PT1874313E (pt) 2010-10-21
CA2605972C (en) 2011-08-02
EP1874313B8 (en) 2010-09-01
EP1874313A1 (en) 2008-01-09
ES2349657T3 (es) 2011-01-10
RU2007139457A (ru) 2009-06-10
DE602006015796D1 (de) 2010-09-09
JO2658B1 (en) 2012-06-17
WO2006117608A1 (en) 2006-11-09
US8334298B2 (en) 2012-12-18
RU2416410C2 (ru) 2011-04-20
US20080293693A1 (en) 2008-11-27
CA2605972A1 (en) 2006-11-09
TW200724141A (en) 2007-07-01
PL1874313T3 (pl) 2011-03-31
TWI315668B (en) 2009-10-11
EP1874313B1 (en) 2010-07-28

Similar Documents

Publication Publication Date Title
DK1874313T3 (da) Behandling eller forebyggelse af ovarielt hyperstimulationssyndrom (OHSS) ved anvendelse af en dopaminagonist
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
EA200601766A1 (ru) Производные имидазола
DK1888094T3 (da) Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser
CL2008000579A1 (es) Compuestos derivados de isoxazolina espiro condensada, inhibidores de la proteasa serina; composicion farmaceutica; uso en el tratamiento de una infeccion causada por el virus de la hepatitis c (hcv); y un metodo para reducir contaminacion por hcv de un equipo de laboratorio.
NO20090453L (no) Hepatitt C Virusinhibitorer
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
EA200801118A1 (ru) Способ ингибирования flt3 киназы
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
EA201200429A1 (ru) Производные циклопропиламида
ATE519480T1 (de) Konzentrierte flüssige schilddrüsenhormonzusammensetzung
CL2009000803A1 (es) Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
EA200970529A1 (ru) Антивирусная композиция и способ ее применения
EA200970373A1 (ru) АНТИДЕПРЕССАНТ, НЕЙРОПРОТЕКТОР, ИНГИБИТОР ОТЛОЖЕНИЙ β-АМИЛОИДА ИЛИ СРЕДСТВО, ЗАМЕДЛЯЮЩЕЕ СТАРЕНИЯ, СОДЕРЖАЩИЕ ГЕТЕРОЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ КОНКРЕТНОЙ СТРУКТУРЫ
CL2007001254A1 (es) Metodo de operacion de un monitor de evento tal como una solicitud de acceso, modificacion y/o remocion de objetos y dicho monitor, para monitorear el flujo de eventos entre una aplicacion front-end y su servidor back-end.
BRPI0512642A (pt) aparelho e método de proteção contra corrosão
WO2011153458A3 (en) Compositions and methods for inhibition of or treatment of dengue virus infection